Responses
Regular and young investigator award abstracts
Novel single-agent immunotherapies
696 Brentuximab vedotin, a CD30-directed antibody-drug conjugate, selectively depletes activated Tregs in vitro and in vivo
Compose a Response to This Article
Other responses
No responses have been published for this article.
